Medicaid Provider Alert: Provider revalidation has begun and those not completing the process risk disenrollment. Check your account now to learn when your revalidation is due. More information here.

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: December 2, 2009

Drug Name	Review Type	Class	Manufacturer
Tyvaso	New Drug Initial Review	Pulmonary Arterial Hypertension	United Therapeutics
Renvela	New Drug Initial Review	Phosphate Binder	Genzyme
Embeda	New Drug Initial Review	Narcotic	King
Stelara	New Drug Initial Review	Biologic Response Modifier	J&J/Centocor Ortho Biotech
Simponi	New Drug Initial Review	Biologic Response Modifier	Centocor Ortho Biotech
Vivitrol	New Drug Initial Review	Opioid Antagonist	Alkermes
Extavia	New Drug Initial Review	Multiple Sclerosis Agent	Novartis
Zenpep	New Drug Initial Review	Pancreatic Enzymes	Eurand
Lamictal XR	New Drug Initial Review	Anticonvulsant	GlaxoSmithKline
Lamictal ODT	New Drug Initial Review	Anticonvulsant	GlaxoSmithKline
Vyvanse	New Drug Appeal	Stimulant/ADHD Agent	Shire
Bromfed DM	New Drug Appeal	Non-Narcotic Cough/Cold	Morton Grove/Wockhardt
Savella	New Drug Appeal	SNRI	Forest
Nascobal	New Drug Appeal	Vitamin	Strativa
Saphris	New Drug Appeal	Atypical Antipsychotic	Schering-Plough
Moxatag	New Drug Appeal	Antibiotic	MiddleBrook

Footer